3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2
2
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
27
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Burkitt Lymphoma
9
Leukemia
6
Recurrence
4
Lymphoma
4
Prostatic Neoplasms
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Biphenotypic, Acute
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Neoplasms, Plasma Cell
2
Immunoglobulin Light-chain Amyloidosis
2
Hodgkin Disease
2
Down Syndrome
2
Breast Neoplasms
2
Vomiting
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Smoldering Multiple Myeloma
1
Nausea
1
Malignant Neoplasms of Male Genital Organs
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Inflammatory Breast Neoplasms
1
Hypersensitivity
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Interventions
Rituximab
14
pirtobrutinib
6
ibrutinib
4
Vincristine
4
Doxorubicin
4
Prednisone
3
Cytarabine
3
Cyclophosphamide
3
zanubrutinib
2
acalabrutinib
2
Methotrexate
2
Etoposide
2
Bendamustine Hydrochloride
2
venetoclax
1
tositumomab I-131
1
idelalisib
1
ibritumomab tiuxetan
1
etoposide phosphate
1
entecavir
1
cirmtuzumab
1
axicabtagene ciloleucel
1
VAP-cyclo protocol
1
Tenofovir
1
Radiotherapy
1
Melphalan
1
Ifosfamide
1
Gemcitabine
1
Everolimus
1
Drug Therapy
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, B-Cell
×
Calcium Dobesilate
×
Clear all
NCT06230224
2026-05-11
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3
Active not recruiting
216 enrolled